Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer

PURPOSE: Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR)-2. This study was conducted to assess the efficacy and safety of apatinib combined with exemestane in patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Aihua, Nong, Li, Wang, Hongxue, Jia, Yuxian, Zhong, Wuning, Qin, Fanghui, Wang, Han, Tang, Jing, Liu, Yan, Lu, Yongkui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578185/
https://www.ncbi.nlm.nih.gov/pubmed/37831547
http://dx.doi.org/10.1080/15384047.2023.2265055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578185/
https://www.ncbi.nlm.nih.gov/pubmed/37831547
http://dx.doi.org/10.1080/15384047.2023.2265055

Ejemplares similares